6-Quinolinesulfonamide, 1,2-dihydro-2-oxo- | 855766-77-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-Quinolinesulfonamide, 1,2-dihydro-2-oxo-
• 英文别名: 2-oxo-1H-quinoline-6-sulfonamide
• CAS: 855766-77-7
• 化学式: C₉H₈N₂O₃S
• 分子量: 224.24
• InChiKey: OOLIMCWDWFKSJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA O-GLCNAC TRANSFÉRASE ET LEURS UTILISATIONS
  申请人：HARVARD COLLEGE

  公开号：WO2020047251A1

  公开（公告）日：2020-03-05

  Provided herein are O-GlcNAc transferase (OGT) inhibitor compounds of Formula (I'), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., diabetes and complications thereof, neurodegenerative diseases, proliferative diseases such as cancers, autoimmune diseases, and inflammatory diseases) in a subject. Provided are methods of inhibiting OGT in a subject or biological sample.

  本发明提供了O-葡萄糖醛酸转移酶（OGT）抑制化合物，其化学公式为（I'），以及药用可接受的盐、溶剂化物、水合物、多晶型、共晶、互变异构体、对映异构体、同位素标记衍生物、前药和由其组成的组合物。还提供了涉及本发明的化合物或组合物用于治疗和/或预防受试者疾病（例如，糖尿病及其并发症、神经退行性疾病、增殖性疾病如癌症、自身免疫病和炎症性疾病）的方法和试剂盒。还提供了在受试者或生物样本中抑制OGT的方法。
• Alkynyl dihydroquinoline sulfonamide compounds
  申请人：AMGEN INC.

  公开号：US10729684B2

  公开（公告）日：2020-08-04

  The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

  本发明提供的式 I 化合物及其药学上可接受的盐类是电压门控钠通道，特别是 Nav1.7 的抑制剂。这些化合物可用于治疗与钠通道活性相关的疾病，如疼痛、咳嗽和瘙痒。此外，还提供了含有本发明化合物的药物组合物。
• ALKYNYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS
  申请人：AMGEN INC.

  公开号：US20180369226A1

  公开（公告）日：2018-12-27

  The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.